Detail akcie Novartis AG online

Business Summary: Novartis AG is a Switzerland-based pharmaceutical company. The Company develops, manufactures, and markets branded and generic prescription drugs, active pharmaceutical ingredients (APIs), biosimilars and ophthalmic products. The Company uses science and digital technologies for treatments in the disease areas of immunology, dermatology, cancer, ophthalmology, neuroscience, respiratory, cardiovascular, renal and metabolism. The business activities of the Company are divided into two segments: Innovative Medicines, which includes innovative patent-protected prescription medicines for blood pressure, cancer and other ailments, and Sandoz, which includes generic pharmaceuticals and biosimilars.
Financial Summary: BRIEF: For the fiscal year ended 31 December 2024, Novartis AG revenues increased 11% to $51.72B. Net income before extraordinary items increased 39% to $11.94B. Revenues reflect Cardiovascular, Renal and Metabolism - Entresto segment increase of 30% to $7.82B, Immunology - Cosentyx segment increase of 23% to $6.14B, United States segment increase of 18% to $21.15B, Other Foreign- segment increase of 17% to $18.51B.